Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Conference News AHA 2024

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Yael L. Maxwell

November 20, 2024

News Conference News AHA 2024

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

Caitlin E. Cox

November 18, 2024

Presentation TCT 2024

TCT 680: Myocardial Infarction With Non-Obstructive Coronary Arteries (MINOCA): Full Clinical Picture, Risk Factors, and NT-proBNP/Troponin Ratio as a Novel Diagnostic Method

Presenter: Natalia Krajewska

October 30, 2024

Presentation TCT 2024

TCT 719: Coronary Microvascular Resistance and High Sensitivity Troponin After Elective Percutaneous Coronary Intervention

Presenter: Danilo Maksud

October 30, 2024

Presentation TCT 2024

TCT 105: Predictors of Post-Procedural Troponin Increase in Patients Undergoing Elective Percutaneous Coronary Intervention

Presenter: Mauro Gitto

October 29, 2024

News Conference News TCT 2024

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

Michael O'Riordan

October 28, 2024

Presentation TCT 2024

TCT 1108: Skyrocketing Troponin After a Motor Vehicle Crash: A Traumatic Dilemma

Presenter: Rahul Annabathula

October 28, 2024

News Conference News HFSA 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

L.A. McKeown

October 04, 2024

News Conference News HFSA 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

Michael O'Riordan

October 03, 2024

News Daily News

New Guidelines for CV Care in Patients Undergoing Noncardiac Surgery

Michael O'Riordan

September 24, 2024

News Conference News ESC 2024

AI Tool Fails to Boost Outcomes in ED Triage of Suspected CV Conditions

Caitlin E. Cox

September 12, 2024

News Opinion Editor's Corner

What’s Going to Be Hot at ESC 2024

Shelley Wood

August 23, 2024

News Daily News

Point-of-Care High-Sensitivity Assay for Troponin I Compares Well With Central Labs

L.A. McKeown

August 15, 2024

News Daily News

CMR Could Change Diagnosis, Management of Suspected NSTEMI: OxAMI

Yael L. Maxwell

July 18, 2024

News Industry News

CellProthera announces positive Phase I/IIb data for ProtheraCytes® cell therapy in acute myocardial infarction

May 29, 2024

News Daily News

Certain Periprocedural MIs Don’t Matter, New Data Allege

Michael O'Riordan

May 09, 2024

News Daily News

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Yael L. Maxwell

May 03, 2024

News Conference News ACC 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Michael O'Riordan

April 07, 2024

News Daily News

ACC Chest Pain Pathway Performs Well Overall, Less So for Those With CAD

Yael L. Maxwell

March 28, 2024

News Daily News

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

Michael O'Riordan

February 01, 2024

Advertisement

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

TCT 680: Myocardial Infarction With Non-Obstructive Coronary Arteries (MINOCA): Full Clinical Picture, Risk Factors, and NT-proBNP/Troponin Ratio as a Novel Diagnostic Method

TCT 719: Coronary Microvascular Resistance and High Sensitivity Troponin After Elective Percutaneous Coronary Intervention

TCT 105: Predictors of Post-Procedural Troponin Increase in Patients Undergoing Elective Percutaneous Coronary Intervention

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

TCT 1108: Skyrocketing Troponin After a Motor Vehicle Crash: A Traumatic Dilemma

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

New Guidelines for CV Care in Patients Undergoing Noncardiac Surgery

AI Tool Fails to Boost Outcomes in ED Triage of Suspected CV Conditions

What’s Going to Be Hot at ESC 2024

Point-of-Care High-Sensitivity Assay for Troponin I Compares Well With Central Labs

CMR Could Change Diagnosis, Management of Suspected NSTEMI: OxAMI

CellProthera announces positive Phase I/IIb data for ProtheraCytes® cell therapy in acute myocardial infarction

Certain Periprocedural MIs Don’t Matter, New Data Allege

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

ACC Chest Pain Pathway Performs Well Overall, Less So for Those With CAD

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content